Sangamo Therapeutics, Inc. (SGMO) Shares Bought by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC raised its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 97.4% during the second quarter, Holdings Channel reports. The institutional investor owned 58,378 shares of the biopharmaceutical company’s stock after buying an additional 28,802 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Sangamo Therapeutics were worth $514,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. HighTower Advisors LLC increased its stake in shares of Sangamo Therapeutics by 0.3% in the first quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 100 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Sangamo Therapeutics by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock valued at $670,000 after buying an additional 513 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 780 shares in the last quarter. American International Group Inc. increased its stake in shares of Sangamo Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 42,747 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 2,818 shares in the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of Sangamo Therapeutics by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company’s stock valued at $502,000 after buying an additional 7,693 shares in the last quarter. 58.25% of the stock is owned by hedge funds and other institutional investors.

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) opened at 9.50 on Friday. The stock’s 50 day moving average price is $9.05 and its 200-day moving average price is $6.12. Sangamo Therapeutics, Inc. has a 1-year low of $2.65 and a 1-year high of $10.50. The stock’s market capitalization is $683.42 million.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 42.68% and a negative net margin of 246.39%. The firm had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $5.82 million. During the same period in the previous year, the firm earned ($0.38) earnings per share. The company’s revenue was up 124.3% on a year-over-year basis. Equities research analysts anticipate that Sangamo Therapeutics, Inc. will post ($0.93) EPS for the current fiscal year.

WARNING: This report was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/2802484/sangamo-therapeutics-inc-sgmo-shares-bought-by-gilder-gagnon-howe-co-llc.html.

Several brokerages recently issued reports on SGMO. ValuEngine raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Piper Jaffray Companies set a $8.00 price objective on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday. Wedbush reissued a “neutral” rating and issued a $4.00 price objective (down from $6.00) on shares of Sangamo Therapeutics in a research note on Tuesday, May 16th. BidaskClub downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $17.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, June 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $9.67.

In other news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the completion of the transaction, the vice president now directly owns 35,517 shares of the company’s stock, valued at $355,170. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 8.10% of the stock is currently owned by insiders.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.